Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10–20% of patients with EGFRm+ NSCLC have uncommon EGFR variants, defined as mutations other th...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Petros Christopoulos, Franziska Herster, Petra Hoffknecht, Markus Falk, Markus Tiemann, Hans-Georg Kopp, Andre Althoff, Anja Stammberger, Eckart Laack
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	EGFR non-small cell lung cancer (NSCLC) afatinib uncommon mutation tyrosine kinase inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1347742/full